Jubilant Pharmova Limited (JUBLPHARMA.BO)
INR 881.1
(-0.37%)
INR 881.1
(-0.37%)
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2023 | 12.89 Billion INR | -6.59% |
| 2022 | 13.8 Billion INR | 10.01% |
| 2021 | 12.54 Billion INR | 11.11% |
| 2020 | 11.29 Billion INR | -38.8% |
| 2019 | 18.45 Billion INR | 30.2% |
| 2018 | 14.17 Billion INR | 1.87% |
| 2017 | 13.91 Billion INR | 14.01% |
| 2016 | 12.2 Billion INR | 1.44% |
| 2015 | 12.03 Billion INR | -1.79% |
| 2014 | 12.24 Billion INR | -8.68% |
| 2013 | 13.41 Billion INR | 20.18% |
| 2012 | 11.16 Billion INR | 9.41% |
| 2011 | 10.2 Billion INR | 47.58% |
| 2010 | 6.91 Billion INR | 0.05% |
| 2009 | 6.9 Billion INR | 16.01% |
| 2008 | 5.95 Billion INR | 36.93% |
| 2007 | 4.34 Billion INR | 23.14% |
| 2006 | 3.53 Billion INR | 13.33% |
| 2005 | 3.11 Billion INR | 60.88% |
| 2004 | 1.93 Billion INR | 47.42% |
| 2003 | 1.31 Billion INR | 0.0% |
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2024 Q2 | 11.61 Billion INR | 0.0% |
| 2024 Q1 | - INR | -100.0% |
| 2023 Q3 | - INR | -100.0% |
| 2023 Q1 | - INR | -100.0% |
| 2023 Q4 | 12.89 Billion INR | 0.0% |
| 2023 Q2 | 13.28 Billion INR | 0.0% |
| 2023 FY | 12.89 Billion INR | -6.59% |
| 2022 Q2 | 14.09 Billion INR | 0.0% |
| 2022 Q4 | 13.8 Billion INR | 0.0% |
| 2022 FY | 13.8 Billion INR | 10.01% |
| 2022 Q1 | - INR | -100.0% |
| 2022 Q3 | - INR | -100.0% |
| 2021 Q1 | - INR | -100.0% |
| 2021 Q2 | 11.79 Billion INR | 0.0% |
| 2021 Q3 | - INR | -100.0% |
| 2021 Q4 | 12.54 Billion INR | 0.0% |
| 2021 FY | 12.54 Billion INR | 11.11% |
| 2020 Q1 | - INR | -100.0% |
| 2020 FY | 11.29 Billion INR | -38.8% |
| 2020 Q3 | - INR | -100.0% |
| 2020 Q4 | 11.29 Billion INR | 0.0% |
| 2020 Q2 | 18.1 Billion INR | 0.0% |
| 2019 Q2 | 16.44 Billion INR | 0.0% |
| 2019 FY | 18.45 Billion INR | 30.2% |
| 2019 Q1 | - INR | -100.0% |
| 2019 Q3 | - INR | -100.0% |
| 2019 Q4 | 18.45 Billion INR | 0.0% |
| 2018 FY | 14.17 Billion INR | 1.87% |
| 2018 Q4 | 14.17 Billion INR | 0.0% |
| 2018 Q3 | - INR | -100.0% |
| 2018 Q2 | 15.54 Billion INR | 0.0% |
| 2018 Q1 | - INR | -100.0% |
| 2017 FY | 13.91 Billion INR | 14.01% |
| 2017 Q2 | 12.83 Billion INR | 0.0% |
| 2017 Q3 | - INR | -100.0% |
| 2017 Q4 | 13.91 Billion INR | 0.0% |
| 2017 Q1 | - INR | -100.0% |
| 2016 FY | 12.2 Billion INR | 1.44% |
| 2016 Q2 | 12.29 Billion INR | 0.0% |
| 2016 Q1 | - INR | -100.0% |
| 2016 Q4 | 12.2 Billion INR | 0.0% |
| 2016 Q3 | - INR | -100.0% |
| 2015 Q3 | - INR | -100.0% |
| 2015 FY | 12.03 Billion INR | -1.79% |
| 2015 Q4 | 12.03 Billion INR | 0.0% |
| 2015 Q2 | 12.85 Billion INR | 0.0% |
| 2015 Q1 | - INR | -100.0% |
| 2014 Q4 | 12.24 Billion INR | 0.0% |
| 2014 FY | 12.24 Billion INR | -8.68% |
| 2014 Q2 | 13.93 Billion INR | 0.0% |
| 2014 Q1 | - INR | -100.0% |
| 2014 Q3 | - INR | -100.0% |
| 2013 Q4 | 13.41 Billion INR | 0.0% |
| 2013 FY | 13.41 Billion INR | 20.18% |
| 2013 Q3 | - INR | -100.0% |
| 2013 Q1 | - INR | -100.0% |
| 2013 Q2 | 13.6 Billion INR | 0.0% |
| 2012 Q4 | 11.16 Billion INR | 0.0% |
| 2012 FY | 11.16 Billion INR | 9.41% |
| 2011 FY | 10.2 Billion INR | 47.58% |
| 2011 Q4 | 10.2 Billion INR | 0.0% |
| 2010 FY | 6.91 Billion INR | 0.05% |
| 2009 FY | 6.9 Billion INR | 16.01% |
| 2008 FY | 5.95 Billion INR | 36.93% |
| 2007 FY | 4.34 Billion INR | 23.14% |
| 2006 FY | 3.53 Billion INR | 13.33% |
| 2005 FY | 3.11 Billion INR | 60.88% |
| 2004 FY | 1.93 Billion INR | 47.42% |
| 2003 FY | 1.31 Billion INR | 0.0% |
| Name | Inventory | Inventory Difference |
|---|---|---|
| Alembic Pharmaceuticals Limited | 16.43 Billion INR | 21.535% |
| Aurobindo Pharma Limited | 98.08 Billion INR | 86.852% |
| Glenmark Life Sciences Limited | 6.66 Billion INR | -93.462% |
| Granules India Limited | 13 Billion INR | 0.842% |
| Indoco Remedies Limited | 3.53 Billion INR | -265.264% |
| Achyut Healthcare Limited | 568 Thousand INR | -2270322.535% |
| Ajanta Pharma Limited | 8.28 Billion INR | -55.681% |
| Alkem Laboratories Limited | 26.61 Billion INR | 51.54% |
| Alpa Laboratories Limited | 136.65 Million INR | -9337.041% |
| Brooks Laboratories Limited | 96.1 Million INR | -13318.238% |
| AstraZeneca Pharma India Limited | 2.27 Billion INR | -465.907% |
| Bajaj HealthCare Limited | 1.44 Billion INR | -795.318% |
| Bliss GVS Pharma Limited | 1.18 Billion INR | -988.754% |
| Dr. Reddy's Laboratories Limited | 63.55 Billion INR | 79.708% |
| Eris Lifesciences Limited | 1.89 Billion INR | -582.213% |
| FDC Limited | 3.88 Billion INR | -231.612% |
| Glenmark Pharmaceuticals Limited | 25.13 Billion INR | 48.684% |
| Gufic Biosciences Limited | 2 Billion INR | -543.249% |
| Ind-Swift Laboratories Limited | 104.57 Million INR | -12231.583% |
| Ipca Laboratories Limited | 24.71 Billion INR | 47.817% |
| Jagsonpal Pharmaceuticals Limited | 149.97 Million INR | -8499.053% |
| Krebs Biochemicals & Industries Limited | 97.96 Million INR | -13064.019% |
| Lasa Supergenerics Limited | 190.43 Million INR | -6671.9% |
| Laurus Labs Limited | 18.45 Billion INR | 30.119% |
| Lupin Limited | 49.53 Billion INR | 73.968% |
| Mankind Pharma Limited | 15.53 Billion INR | 16.985% |
| Medicamen Biotech Limited | 593.75 Million INR | -2071.951% |
| Medico Remedies Limited | 163.37 Million INR | -7793.642% |
| Megasoft Limited | - INR | -Infinity% |
| NATCO Pharma Limited | 7 Billion INR | -84.097% |
| Piramal Pharma Limited | 21.75 Billion INR | 40.732% |
| RPG Life Sciences Limited | 1.01 Billion INR | -1176.832% |
| Sigachi Industries Limited | 707.2 Million INR | -1723.511% |
| Sun Pharmaceutical Industries Limited | 98.68 Billion INR | 86.932% |
| Suven Pharmaceuticals Limited | 2.31 Billion INR | -457.796% |
| Syncom Formulations (India) Limited | 210.81 Million INR | -6017.212% |
| Unichem Laboratories Limited | 7.04 Billion INR | -83.006% |
| Wanbury Limited | 360.23 Million INR | -3479.915% |
| Windlas Biotech Limited | 621.89 Million INR | -1973.679% |
| ZIM Laboratories Limited | 812.62 Million INR | -1486.948% |
| Zydus Lifesciences Limited | 34.41 Billion INR | 62.532% |
| Sun Pharma Advanced Research Company Limited | - INR | -Infinity% |
| Divi's Laboratories Limited | 31.84 Billion INR | 59.497% |
| Hester Biosciences Limited | 755.81 Million INR | -1606.249% |
| Procter & Gamble Health Limited | 1.09 Billion INR | -1081.926% |
| Amrutanjan Health Care Limited | 289.04 Million INR | -4361.558% |
| Bal Pharma Limited | 878.11 Million INR | -1368.602% |
| Strides Pharma Science Limited | 11.26 Billion INR | -14.505% |
| Venus Remedies Limited | 1.21 Billion INR | -959.742% |
| Aarti Pharmalabs Limited | 6.42 Billion INR | -100.604% |
| Nectar Lifesciences Limited | 7.09 Billion INR | -81.851% |
| Shilpa Medicare Limited | 3.44 Billion INR | -273.875% |
| Aarti Drugs Limited | 4.85 Billion INR | -165.41% |
| IOL Chemicals and Pharmaceuticals Limited | 4.24 Billion INR | -203.55% |
| Suven Life Sciences Limited | 7.08 Million INR | -181918.349% |
| Ind-Swift Limited | 640.91 Million INR | -1912.123% |
| Valiant Laboratories Limited | 100.15 Million INR | -12776.171% |
| J. B. Chemicals & Pharmaceuticals Limited | 5.02 Billion INR | -156.632% |
| Solara Active Pharma Sciences Limited | 3.59 Billion INR | -258.521% |
| Themis Medicare Limited | 705.74 Million INR | -1727.294% |
| Hikal Limited | 3.03 Billion INR | -324.602% |
| Torrent Pharmaceuticals Limited | 22.79 Billion INR | 43.414% |
| Sequent Scientific Limited | 3.46 Billion INR | -272.467% |
| Novartis India Limited | 448.6 Million INR | -2774.721% |
| Wockhardt Limited | 6.4 Billion INR | -101.5% |
| Biofil Chemicals and Pharmaceuticals Limited | 25.49 Million INR | -50478.499% |
| Neuland Laboratories Limited | 3.5 Billion INR | -268.014% |
| Morepen Laboratories Limited | 2.48 Billion INR | -418.757% |
| Kilitch Drugs (India) Limited | 39.88 Million INR | -32237.011% |
| Mangalam Drugs & Organics Limited | 1.23 Billion INR | -943.03% |